Evaluation of the Sildenafil Effects on Forced  Expiratory Volume in One Second (Fev1) in Patients  with Chronic Obstructive Pulmonary Disease (Copd)

Mohammad–Mahdi Zahmatkesh; Shamila Faramarzi; Shahab Shahabi Shahmiri; Mohammad Reza Sharif; Mehdi Taghiyan; Vahid Naemy; Mohammad Purfakharan; Masoud Mahmoodian

Volume : III, Issue : XI, November - 2013

Evaluation of the Sildenafil Effects on Forced Expiratory Volume in One Second (Fev1) in Patients with Chronic Obstructive Pulmonary Disease (Copd)

Mohammad Mahdi Zahmatkesh, Shamila Faramarzi, Shahab Shahabi Shahmiri, Mohammad Reza Sharif, Mehdi Taghiyan, Vahid Naemy, Mohammad Purfakharan, Masoud Mahmoodian

Abstract :

Background: sildenafil have been shown in small studies to decrease pulmonary arterial hypertension (PAH). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and systemic circulation may occur. According to Sildenafil effects in pulmonary disease especially in PAH, this study was conducted to evaluate the safety and efficacy of Sildenafil as a rapid acting drug for treatment of COPD patients. METHODS AND SUBJECTS Twenty three patients suffering from stable COPD who referred to Rasoul–e–Akram Hospital, Tehran, Iran in 2008 participated in this prospective quasi–experimental trial. These 23 patients received single dose of 50mg oral sildenafil. FEV1 has been measured before and after drug administration.The data were analyzed using SPSS v.16 software for Windows (SPSS Inc, Chicago, IL, USA). Parameters such as frequency, mean, mode and standard deviation (S.D.) were reported. Kolmogronov Smirnov (K.S) test was performed to evaluate normal distribution of the quantitative variables. Results: The results of analysis show that sildenafil significantly increase FEV1 from 1.29(SD=0.61) to 1.43(SD=0.77) (P<0.001).The sex, pulmonary hypertension and smoking had not significant effect on changes of FEV1 before and after treatment with P value of 0.52, 0.062 and 0.935, respectively. Also aforementioned factors had not significant effect on changes of respiratory symptoms before and after treatment with P value of 0.448, 0.200 and 0.382, respectively. Conclusion: The usage of Sildenafil in the improvement of COPD is better to be recommended after performing and reporting the results of phase II or III human trials with a greater sample size.